Closed · RFA-HL-16-001 · CFDA 93.838 · Discretionary

Molecular Imaging of the Lung - Phase 2 (R01)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $450K
Award range
Closed
Status
June 15, 2015
Close date
5
Expected awards

The verdict

Molecular Imaging of the Lung - Phase 2 (R01) is a closed discretionary listing from National Institutes of Health that offered Up to $450,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $450K
award range
Closed
application status
5
expected awards
93.838
CFDA program

Archived opportunity record

Molecular Imaging of the Lung - Phase 2 (R01) is closed (last close June 15, 2015). The parent program page for CFDA 93.838 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 15, 2015

Posted Mar 17 Closes Jun 15

Est. Total Funding

$3,500,000

Expected Awards

5

Instrument

Grant

Description

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to develop novel in vivo imaging technologies using molecular probes that target pathways or cells involved in the pathobiology of pulmonary diseases. The long-term goal of this program is to develop novel molecular imaging entities and approaches that facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress of cell-specific drug delivery and therapies.The previous FOA (RFA-HL-12-036 - Phase 1) supported projects to develop and validate innovative novel imaging agents and approaches that included target selection, probe development and production, and initial characterization of the probe. Phase 2 of this initiative will support studies that advance translation of identified probes and associated imaging approaches from animal models into applicability for human lung diseases. Phase 2 studies must include work performed in vivo using appropriate animal models of lung diseaseand studies using human tissues and/or cells. Applications proposing Investigational New Drug (IND)-enabling studies of novel probes and imaging approaches are encouraged. Applicants are not required to have been funded in Phase 1 (RFA-HL-12-036) in order to submit applications for Phase 2.

Wide-open applicant board · 15 Grants.gov doors

Molecular Imaging of the Lung - Phase 2 (R01) prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Health (HL). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Molecular Imaging of the Lung - Phase 2 (R01) is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.838 may publish future NOFOs under the same assistance listing. Open program
  • Lung Disease Research indexes 90 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants